Ibogaine for OCD: What the Evidence Actually Shows

Obsessive-compulsive disorder (OCD) is a chronic psychiatric condition defined by two features. Obsessions are intrusive, unwanted thoughts, images, or urges that provoke marked distress. Compulsions are repetitive behaviours or mental acts performed to neutralise that distress — washing, checking, counting, reassurance-seeking, or silent reviewing. The relief is brief, and the cycle reinforces itself.

OCD is classified under ICD-10 code F42. It is not a personality trait or a preference for tidiness, and people with OCD typically recognise their fears as excessive while remaining unable to disengage from them.

The National Institute of Mental Health reports, from the National Comorbidity Survey Replication, that an estimated 1.2% of US adults had OCD in the past year and 2.3% met criteria at some point in their lives. Past-year prevalence was higher in women (1.8%) than men (0.5%). Among adults with past-year OCD, 50.6% had serious impairment on the Sheehan Disability Scale — one of the highest serious-impairment proportions recorded for any anxiety-related disorder.

Two features of the illness matter for everything that follows.

• Treatment is often delayed for years. A 2023 systematic review in the Journal of Personalized Medicine found mean duration of untreated illness across studies ranging from 7.0 to 20.9 years, and reported response rates of 41% when untreated illness exceeded 24 months versus 69% below that threshold.
• Symptoms wax and wane naturally. Severity fluctuates with stress, life events, and context. Any uncontrolled report of improvement — after any intervention — has to be weighed against that background variability.

OCD has a genuine, RCT-backed treatment evidence base. Any experimental option has to be judged against it.

First-line pharmacotherapy is a serotonin reuptake inhibitor: escitalopram, fluoxetine, sertraline, paroxetine, or fluvoxamine, plus the tricyclic clomipramine. OCD generally requires higher doses and longer trials — often 10 to 12 weeks — than depression does. Response is conventionally defined as a ≥35% reduction on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS).

First-line psychotherapy is exposure and response prevention (ERP), a structured form of cognitive behavioural therapy in which a person deliberately contacts feared triggers without performing the compulsion. Meta-analytic work finds ERP combined with pharmacotherapy outperforms medication alone. Combination treatment is standard practice for moderate-to-severe illness.

The limitations are real and well documented:

• A 2025 narrative review in the Journal of Clinical Medicine notes that 40–60% of patients show only partial or no response to SSRIs at standard doses, which is why supratherapeutic dosing strategies are studied at all.
• Roughly half of patients do not respond optimally to CBT or ERP even when combined with medication.
• Augmentation with dopamine antagonists carries the strongest evidence among next-step strategies, but benefits a minority of those who try it.
• Neuromodulation exists for the most refractory cases. The FDA granted a Humanitarian Device Exemption in February 2009 for deep brain stimulation of the anterior limb of the internal capsule, supported by responder rates of 33–78%. A 2021 Frontiers in Surgery analysis found uptake actually fell after approval — 50% of eligible candidates proceeded post-HDE versus 86% before — largely because of insurance coverage.

That gap between what works and who can access it is the demand that experimental options are marketed into.

Ibogaine is a psychoactive indole alkaloid from the root bark of Tabernanthe iboga, studied almost exclusively as an experimental intervention for substance use disorders. The argument for extending it to OCD is theoretical, and it runs through compulsivity.

Ibogaine has an unusually promiscuous receptor profile. It acts as an NMDA receptor antagonist, binds kappa- and mu-opioid receptors, sigma-1 and sigma-2 receptors, 5-HT2A and 5-HT3 receptors, and α3β4 nicotinic acetylcholine receptors, and inhibits the serotonin and dopamine transporters — most of these in the micromolar range. It is metabolised largely by CYP2D6 into noribogaine, a long-lived active metabolite. Preclinical work also links ibogaine to sustained upregulation of glial cell line-derived neurotrophic factor (GDNF).

OCD, meanwhile, is understood as a disorder of cortico-striato-thalamo-cortical (CSTC) circuits, with an apparent shift from goal-directed action toward rigid, habitual responding driven by the dorsal striatum, and with glutamate–GABA imbalance documented across those circuits.

The bridging claim is that compulsive drug use and compulsive rituals share circuitry, so a drug that appears to interrupt one might interrupt the other.

The honest reading of that argument:

• It is a chain of inferences, not a demonstrated pathway. Shared circuitry does not predict shared drug response — SSRIs are first-line for OCD and are not effective treatments for opioid or stimulant dependence.
• Ibogaine's human data are entirely in substance use disorders, and even there they are open-label and uncontrolled.
• We could not identify any published study of ibogaine in standard preclinical OCD models — marble burying, signal attenuation, or quinpirole-induced compulsive checking. The screening step that normally precedes human study has not been reported.

This section is short because the literature is.

As of this writing, no clinical trial, case series, or case report of ibogaine used to treat OCD has been published in the peer-reviewed literature. Not a negative study. Not a small positive study. Nothing.

What does exist:

• One narrative review. Nicolas M., "Ibogaine's potential role in supporting reward system recovery across diagnostic boundaries," published in Frontiers in Pharmacology on 4 December 2025, proposes that GDNF-driven plasticity plus glutamate and dopamine modulation could restore reward-circuit function across addiction, PTSD, eating disorders, and OCD. On OCD the paper is explicit that this is speculation: it states that no large-scale ibogaine trials exist and that ibogaine's activity makes it merely "plausible" it could influence rigid behavioural patterns. It is a single-author narrative review with no new data, and the author lists uncontrolled samples, absent blinding, and polypharmacology among its limitations.
• No registered trial. A search of ClinicalTrials.gov returns a small number of ibogaine studies, covering opioid use disorder, methadone detoxification, opioid withdrawal, alcoholism, and PTSD with traumatic brain injury. None lists OCD as a condition.
• A patent, which is not evidence. US Patent 9,592,239 (inventor Emeline L. Maillet, originally assigned to DemeRx, now atai) explicitly names obsessive-compulsive disorder among claimed indications for ibogaine. Granted in 2017, it contains rodent experiments and prophetic human protocols — proposed designs, not results. A patent is a legal claim of scope, not a demonstration of efficacy.

One further caution. A figure circulating online describes a cohort of 58 patients spanning depression, OCD, and traumatic brain injury with improvement clustering three to seven days after dosing. That figure traces to clinic marketing pages, not a peer-reviewed publication. It has no verifiable methods, no independent raters, and no published outcome data. It should not be treated as evidence.

Readers searching for psychedelics for treatment-resistant OCD are often surprised to learn that a controlled evidence base is emerging — but it is for psilocybin, not ibogaine.

Repeated-dose randomised trial. Moreno and colleagues at the University of Arizona published a randomised clinical trial in the Journal of Psychopharmacology in 2026. Fifteen participants received up to eight weekly sessions of high-dose psilocybin (300 µg/kg), low-dose psilocybin (100 µg/kg), or an active placebo (lorazepam). After at least four high doses, 73.3% met response criteria (≥35% Y-BOCS reduction) and 40% met remission criteria, with effects diminished but still present at six months. No serious adverse events were reported. The sample was fifteen people — the authors themselves flag limited statistical power and generalisability.

Single-dose randomised trial. A Yale group ran a double-blind trial of a single 0.25 mg/kg psilocybin dose against 250 mg niacin as an active control in treatment-resistant OCD. A peer-reviewed qualitative analysis of participants' experiences appeared in Frontiers in Psychiatry in 2025. The trial's primary efficacy results have circulated as a preprint reporting roughly 69% response at one week versus none on niacin — that paper has not completed peer review, and those numbers should be treated as provisional.

Why this matters for anyone weighing ibogaine vs psilocybin for OCD:

• Psilocybin has randomised, blinded, placebo-controlled data in OCD. Ibogaine has none.
• Psilocybin trials in OCD have not reported the QT prolongation signal that dominates ibogaine's safety literature.
• Neither is an approved OCD treatment. Both remain Schedule I in the United States, and psilocybin's OCD samples are still very small.

The comparison does not favour ibogaine. It describes a compound with a plausible story and a compound with early trial data.

Because ibogaine is Schedule I in the United States, people seeking it travel to clinics in jurisdictions where it is unscheduled or tolerated — most often Mexico, and also Costa Rica and Portugal. Oversight varies enormously between providers, and no programme anywhere is an approved OCD treatment.

A responsibly run programme should include, at minimum:

• 12-lead ECG with QTc measurement, and cardiology clearance for any abnormality
• Serum potassium and magnesium, corrected into normal range before dosing
• Liver and renal function testing, full blood count, and pregnancy testing
• Complete medication reconciliation, screening for QT-prolonging and serotonergic agents
• CYP2D6 genotyping where available, to identify poor metabolisers with prolonged noribogaine exposure
• Continuous cardiac telemetry with resuscitation capability on site

One step is specific to OCD and frequently underestimated: almost everyone with treatment-resistant OCD is taking a high-dose SSRI or clomipramine, and clinics require these to be tapered off before dosing because of serotonergic and cardiac interaction risk. That taper is not a formality. It can take weeks — fluoxetine's long half-life means longer still — and withdrawing the only partially effective treatment a person has carries a real risk of symptom exacerbation and discontinuation syndrome during the waiting period. There is no published protocol establishing how to do this safely for OCD specifically.

The acute experience itself involves several hours of intense psychoactive effects followed by an extended recovery, commonly with ataxia, nausea, vomiting, and inability to stand unassisted. Cardiac risk does not end when the visionary phase does: reported deaths have occurred 1.5 to 76 hours after ingestion, which is longer than many clinics monitor.

Ibogaine's safety profile is dominated by cardiac electrophysiology, and a careful setting reduces but does not remove the risk.

Mechanism. Ibogaine and noribogaine block hERG potassium channels. Koenig and Hilber (Molecules, 2015) report IC50 values of approximately 4 µM for ibogaine and 3 µM for noribogaine — concentrations reached at doses actually used. hERG blockade prolongs cardiac repolarisation, lengthening the QT interval and raising the risk of torsades de pointes, ventricular fibrillation, and cardiac arrest.

Magnitude and duration. Reported QTc values in that review ranged from around 480 ms to over 700 ms, and prolongation persisted beyond 24 hours and sometimes longer than a week — far outlasting ibogaine's own half-life, but consistent with noribogaine's.

Outcomes. The review documented 19 fatalities between 1990 and 2008, with further cases since. Hypokalaemia was detectable in every fatality case reviewed, and low potassium both reduces hERG current directly and worsens drug-induced blockade. A 2026 scoping review in Molecules reaches the same conclusion: ibogaine administration belongs in inpatient settings with continuous ECG monitoring, and CYP2D6 variability is a clinically relevant contributor to individual risk.

Interactions that are specific to OCD pharmacotherapy — and this is the sharpest concern on this page:

• SSRIs and SNRIs carry both serotonin-toxicity risk with serotonergic ibogaine and, for citalopram and escitalopram, independent QT prolongation.
• Clomipramine, a mainstay in refractory OCD, is a tricyclic that prolongs QT and is a CYP2D6 substrate — a double liability.
• Paroxetine and fluoxetine inhibit CYP2D6, which can raise ibogaine exposure if a taper is incomplete.
• Antipsychotic augmentation (risperidone, aripiprazole, quetiapine) adds further QT prolongation.
• Ondansetron, routinely used for ibogaine-induced nausea, is itself QT-prolonging.

Generally accepted contraindications include long QT syndrome, structural heart disease, heart failure, uncorrected electrolyte abnormalities, significant hepatic or renal impairment, pregnancy, bipolar I disorder, and psychosis. Nothing has been published on whether an intense psychedelic state helps or worsens intrusive thoughts in someone with harm or contamination obsessions.

Legal status. Ibogaine is a Schedule I controlled substance under the US Controlled Substances Act — high abuse potential, no currently accepted medical use, and a lack of accepted safety under medical supervision. It is not approved for OCD in any country. Recent state-level research funding, including in Texas, is directed at opioid use disorder and veteran mental health, not OCD.

What would actually move this question forward:

• Preclinical work in OCD-relevant models. Marble burying, signal attenuation, and quinpirole-induced compulsive checking are the standard screens. Their absence is the single largest gap.
• Testing the bridging assumption directly — whether GDNF-mediated plasticity affects CSTC circuit function at all, rather than only mesolimbic reward circuitry.
• Analogue development. Non-hallucinogenic, non-cardiotoxic iboga congeners are already in development for other indications. If the mechanistic hypothesis has merit, that path avoids the risk profile that makes ibogaine hard to justify here.
• A prospective registry with Y-BOCS scores and blinded raters for people who travel for treatment regardless — better data than anecdote, at no additional risk.
• Interaction studies with serotonin reuptake inhibitors, since the taper problem is unavoidable in this population.

The bottom line. For OCD specifically, ibogaine has no published human evidence of any kind. What exists is one speculative review, a patent, and clinic marketing — set against a documented, potentially fatal cardiac risk that interacts poorly with the medications people with OCD are usually taking. Where controlled psychedelic data in OCD do exist, they belong to psilocybin.

---

This page is educational information, not medical advice. It does not recommend ibogaine or endorse any clinic. Do not stop or taper an SSRI, clomipramine, or antipsychotic on your own — discontinuation can worsen OCD symptoms. Treatment decisions belong with a treating psychiatrist.